OBJECTIVES:People living with HIV face several challenges as they age, including the potential for polypharmacy and increased susceptibility to drug-related adverse effects. Thus, effective and well-tolerated regimens with minimal or no drug interactions would be useful in this population. We present real-world effectiveness and safety data for individuals aged >50 years who achieved virological suppression (HIV-1 RNA <50 copies/mL) and switched to dolutegravir/lamivudine (DTG/3TC). METHODS:This retrospective, observational, single-centre study conducted in Portugal included individuals aged >50 years who switched to DTG/3TC while virologically suppressed and had ≥12 months of follow-up. Proportions of individuals maintaining virological suppression were described at 12 months; CD4+ cell counts were described at baseline and 12 months. Descriptive subgroup analyses were performed based on age, sex assigned at birth, and availability of historical genotypic resistance results. RESULTS:Overall, 538 individuals aged >50 years were included (74% male; mean age, 62 years; mean time on previous therapy, 160 months). High proportions (intention-to-treat population, 97%; on-treatment population, 98%) of individuals who switched to DTG/3TC maintained virological suppression through 12 months of follow-up. CD4+ cell counts remained stable (mean baseline: 727 cells/mm3 [range 94-2371]; mean month 12: 742 cells/mm3 [range 99-2659]). No individuals experienced virological failure. Nine (2%) individuals discontinued DTG/3TC for non-treatment-related reasons. Proportions with virological suppression at month 12 were similar between on-treatment subgroups by age, sex assigned at birth, and historical genotypic resistance results availability. CONCLUSIONS:DTG/3TC demonstrated robust effectiveness and a good safety profile in individuals aged >50 years with virological suppression in Portugal.

Rationale: The rapid spread of the COVID-19 pandemic throughout the world created serious health, economic and social problems. The aim of this study was to identify a possible association between the outcome of COVID-19 critically ill patients and their demographic characteristics and health status, such as age, gender, metabolic chronic pathologies, and length of hospital stay in the Intensive Care Unit (ICU). Methods: This was an observational retrospective clinical cohort study, conducted in a central Lisbon Hospital, with critically ill patients admitted to the ICU due to COVID-19 diagnosis and developing severe complications, during the year 2020. Results: Data from 238 patients from the ICU were analyzed. They were mostly males (71%, n=169) with a mean age of 65.6±13.6. High blood pressure (HBP) was identified as the most prevalent comorbidity (69.3%, n=165), followed by dyslipidemia and type 2 diabetes, with 35.3% (n=84) and 34% (n=81), respectively. Male patients admitted to the ICU had a higher risk of a worse prognosis (OR = 2.142; p=0.048; [IC95%: 1.0 – 4.55]), as well as the elderly, aged 65 years or over (OR = 2.773; p=0.003; [IC95%: 1.4 – 5.49]) and patients with HBP (OR = 2.890; p=0.013; [IC95%: 1.25 – 6.67]). For each day of stay in the ICU, the odds of death increased by 1.8% (OR = 1.018; p=0.014; [IC95: 1.0 – 1.03]). Conclusion: With this study, it was possible to contribute to a better perception of the population hospitalized in the ICU due to COVID-19 and to identify risk factors, such as older age, male gender, and HBP that were associated with a worse prognosis. Also, an increase in length of stay at the ICU was associated with an increased risk of death. References: CUMMINGS, Matthew J. et al. - Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. January (2020). GRASSELLI, Giacomo et al. - Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Journal of the American Medical Association. 2020) PETRILLI, Christopher M. et al. - Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. The BMJ. ZHOU, Fei et al. - Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. Disclosure of Interest: None declared

Rationale: To determine the efficacy of an individualized nutritional intervention approach in patients living with Human Immunodeficiency Virus (PLHIV) with non-alcoholic fatty liver disease (NAFLD).

Background: In the current COVID-19 pandemic, some risk factors for severe disease and death have been identified, including age, male gender, diabetes mellitus, cardiovascular and lung diseases, chronic kidney disease and cancer Although still scarce, current data does not support an increased risk for severe COVID-19 on PLWH [1,2] Our aim was to describe clinical characteristics and outcomes of PLWH with COVID-19 followed in our hospital, a reference centre for emerging infectious diseases in Portugal Materials and methods: Retrospective analysis on cases of PLWH with a confirmed COVID-19 diagnosis between 2 March and 14 July 2020 The data showcased in Table 1 was collected from patient records Proven COVID-19 required a positive SARS-CoV-2 nucleic acid amplification test on respiratory samples Results: We followed 2092 patients with COVID-19, eight of whom were PLWH (six males, mean age 48 ± 15 years) on ART at the time of diagnosis, which included protease inhibitors (PI) in two and tenofovir alafenamide in two Median CD4 + T cell count was 626 (range 14 to 1337) cells/mm3 Seven were virally suppressed and had a CD4 + T cell count =350 cells/mm3, and six had at least one comorbidity other than HIV Two patients received treatment with hydroxychloroquine, both of whom were hospitalised: one with concomitant ankylosing spondylitis on methotrexate and the other diagnosed with SARS-CoV-2 pneumonia while hospitalised for candidaemia The latter was a 67-year-old HIV-2 infected patient on a failing ART regimen without immune recovery and with detectable HIV viraemia, and the only casualty in our cohort He had multiple comorbid conditions and required treatment with supplemental oxygen therapy Seven patients were classified as having mild disease, six of whom currently considered fully recovered with a median 40 5 days (range 21 to 74 days) until two consecutive negative SARS-CoV-2 PCR tests Conclusions: PLWH accounted for \u003c 0 4% of patients with COVID-19 in our centre PLWH may still get infected during PI-and/or tenofovir-based ART A severe clinical picture among those with viral suppression on ART was not seen thereby adding to the growing body of evidence supporting the notion that adequately controlled HIV does not by itself place one at increased risk for severe disease or excess mortality

Circumference (MUAC), Triceps Skinfold Thickness (TSF), Mid Arm Muscle Circumference (MAMC), Albumin, Transferrin, Cholesterol. BMI, TSF, MAMC, biochemical parameters a Nutritional and Prognostic Score ranging 0 6 was created. Results: 234 patients, (39 94 years). Cancers: larynx (79), oral cavity (72), pharynx (43), proximal oesophagus (26) and other tissues (14). 149 patients died, 33 still in the Artificial Nutrition Outpatients Consultation, 36 resume oral feeding. NRS 2002 3 and caloric needs under 50% showed in all patients. IMC (12.7 43); 189, 197 and 168 displayed a low, respectively, MUAC, TSF and MAMC. Laboratory values with 91, 155 and 119 patients displayed a low, respectively, albumin, transferrin and cholesterol. Nutritional and Prognostic Score showed that lower scores are associated with lower survival rates (p = 0.029). Conclusion: HNC patients are malnourished when are referred to PEG. All presented malnourished according NRS-2002 and dietary assessment, and most of them presented malnourished according anthropometric and laboratory data. Nutritional and Prognostic score 3 show worst outcome and lower survival, needing special clinical and nutritional support.